No­var­tis ends li­cense agree­ment for can­cer drug with Al­lar­i­ty Ther­a­peu­tics for lack of pay­ment

Al­lar­i­ty Ther­a­peu­tics’ 2018 li­cense agree­ment with No­var­tis for the can­cer drug dovi­tinib has come to an end due to lack of pay­ment, the Boston biotech said in SEC fil­ings.

The agree­ment, which li­censed dovi­tinib to Al­lar­i­ty for an un­spec­i­fied up­front fee, mile­stones and roy­al­ties, end­ed on Jan. 26. No­var­tis wrote Al­lar­i­ty “in­di­cat­ing their de­ci­sion to ter­mi­nate the Agree­ment based on ma­te­r­i­al breach for lack of fi­nan­cial pay­ment,” ac­cord­ing to SEC fil­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER